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Abstract
Background: Influenza A(H3N2), A(H1N1)pdm09 and B viruses co-circulated in 
Europe in 2017-18, predominated by influenza B. WHO-recommended, trivalent 
vaccine components were lineage-mismatched for B. The I-MOVE hospital network 
measured 2017-18 seasonal influenza vaccine effectiveness (IVE) against influenza 
A(H3N2) and B among hospitalised patients (≥65 years) in Europe.
Methods: Following the same generic protocol for test-negative design, hospital teams 
in nine countries swabbed patients ≥65 years with recent onset (≤7 days) severe acute 
respiratory infection (SARI), collecting information on demographics, vaccination sta-
tus and underlying conditions. Cases were RT-PCR positive for influenza A(H3N2) or 
B; controls: negative for any influenza. “Vaccinated” patients had SARI onset >14 days 
after vaccination. We measured pooled IVE against influenza, adjusted for study site, 
age, sex, onset date and chronic conditions.
Results: We included 3483 patients: 376 influenza A(H3N2) and 928 B cases, and 
2028 controls. Most (>99%) vaccinated patients received the B lineage-mismatched 
trivalent vaccine. IVE against influenza A(H3N2) was 24% (95% CI: 2 to 40); 35% (95% 
CI: 6 to 55) in 65- to 79-year-olds and 14% (95% CI: −22 to 39) in ≥80-year-olds. 
Against influenza B, IVE was 30% (95% CI: 16 to 41); 37% (95% CI: 19 to 51) in 65- to 
79-year-olds and 19% (95% CI: −7 to 38) in ≥80-year-olds.
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1  | INTRODUC TION
In Europe, most countries recommend seasonal influenza vaccina-
tion for populations at risk of severe disease, such as older adults 
(aged 65 years and above), or those with co-morbid conditions like 
heart disease or diabetes.1 In February 2017, the World Health 
Organization (WHO) recommendations for the 2017-18 trivalent 
influenza vaccine for the northern hemisphere were to include 
an A/Michigan/45/2015 (H1N1)pdm09-like virus, an A/Hong 
Kong/4801/2014 (H3N2)-like virus and a B/Brisbane/60/2008-like 
virus (B/Victoria lineage). It was also recommended that quadriva-
lent vaccine contains the above three viruses and additionally a B/
Phuket/3073/2013-like virus (B/Yamagata lineage).2
The 2017-18 influenza season in Europe saw co-circulation overall 
of influenza A(H3N2), A(H1N1)pdm09 and B viruses, predominated by 
influenza B, although patterns of dominance varied across countries.3 
Most (97%) of the B viruses typed were B/Yamagata.3 Most of the hos-
pitalised severe acute respiratory illness (SARI) cases (occurring mainly 
in older adults) were caused by infection with influenza B.3
In February 2018, early influenza vaccine effectiveness (IVE) was es-
timated from five European studies, covering all ages and including both 
primary care and hospitalised patients. The IVE against influenza A(H3N2) 
from these studies across nine countries (including two multi-country 
I-MOVE/I-MOVE+ studies) ranged from −42% to 7%, with IVE of 36%-
54% for influenza B and 55%-68% for influenza A(H1N1)pdm09.4
The I-MOVE (Influenza—Monitoring of Vaccines in Europe) hospi-
tal network has provided annual IVE for participating hospitals across 
Europe since 2015. In 2017-18, we measured seasonal IVE against 
hospitalisation with influenza A(H3N2) and B among older adults 
(aged 65 years and over) in the European Union (EU) by age group, 
underlying co-morbid conditions, and vaccination in previous seasons.
2  | METHODS
2.1 | Setting and population
In 2017-18, the I-MOVE hospital network included 23 hospitals from 
10 study sites in nine countries across the EU (one site in each of 
Croatia, Finland, France, Italy, Lithuania, the Netherlands, Portugal, 
and Romania, and two study sites in Spain). The study population 
comprised all community-dwelling elderly (≥65 years) admitted to 
these participating hospitals and diagnosed with SARI within the 
7 days prior to swabbing. All study sites followed the same generic 
protocol, adapted to their setting.5 Following local requirements, 
each local protocol was submitted to and approved by the ethics 
committee(s) in each site. Patient consent was an inclusion criterion 
for the study in each hospital, described in the shared protocol.5
2.2 | Definitions and exclusions
Study methods have been described in detail elsewhere.6 Briefly, 
this multi-centre study used a test-negative design (TND), in which 
cases were hospitalised SARI patients (ie with at least one systemic 
and one respiratory sign or symptom) with confirmed influenza 
A(H1N1)pdm09, A(H3N2) or B using reverse-transcriptase poly-
merase chain reaction (RT-PCR). Patients confirmed with influenza 
A(H1N1)pdm09 were excluded from analyses due to the small sam-
ple size within this population (N = 133). Controls were SARI patients 
who were influenza negative by RT-PCR. The study period, defined 
in each site, was from the onset week of the first to the last con-
firmed case by influenza (sub)type. Patients were considered vacci-
nated if they had SARI onset >14 days after vaccination. Those with 
onset within the 14-day period were excluded from analysis, and any 
patient vaccinated on or after SARI onset was recoded as unvacci-
nated. Any study site with <10 (sub)type-specific cases was excluded 
from pooled analysis.
2.3 | Analysis
We estimated overall adjusted IVE as IVE = (1-ORa) × 100 using a one-
stage analysis of pooled individual data from all sites, for influenza 
A(H3N2) and B. We used logistic regression, with study site as a fixed 
effect. In secondary analyses, IVE for both subtypes was estimated and 
stratified by (a) age group (65-79 years old and 80 years and over); (b) 
presence of at least two underlying chronic conditions (vs one or less); 
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Conclusions: IVE against influenza B was similar to A(H3N2) in hospitalised older 
adults, despite trivalent vaccine and circulating B lineage mismatch, suggesting some 
cross-protection. IVE was lower in those ≥80 than 65-79 years. We reinforce the 
importance of influenza vaccination in older adults as, even with a poorly matched 
vaccine, it still protects one in three to four of this population from severe influenza.
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and (c) vaccination status over the current and previous two seasons, 
divided into five groups: vaccinated in this season only, vaccinated in 
either of the two previous seasons but not in this season, vaccinated 
in the current plus either of the previous two seasons, vaccinated in 
all three seasons, no vaccination in any of the three seasons the refer-
ence group). Penalised logistic regression was used where any stratum 
resulted in small enough numbers to lead to over-fit models (defined as 
a having fewer than 10 cases or controls per model parameter).
For most analyses, the odds ratio (OR) was adjusted (ORa) by 
age, sex, symptom onset date, and presence of at least one, or 
the total number of underlying chronic conditions (none, one, 
two or more). The chronic conditions were selected from diabe-
tes mellitus, cancer, heart/rheumatic/kidney/lung disease, being 
immunocompromised, or being obese. For each country, only 
chronic conditions for which vaccination was recommended were 
included. The ORas for analyses stratified by individual chronic 
condition (where the total number of cases or controls with the 
condition was at least 50) were adjusted as stated above, but not 
by chronic condition. The variables onset date and age were mod-
elled as continuous (using a restricted cubic spline with 3, 4 or 5 
knots) or categorical terms, the choice of which for each model was 
determined by sample size and the Akaike's information criterion. 
The categorical term for onset date, “phase,” was determined for 
each site prior to pooling the data and comprised three categories: 
early (onset dates comprising up to and including the first 10% of 
cases), peak (representing 80% of cases) and late (for the final 10% 
of cases, with the latest onset date). The categorical term for age, 
“age group,” comprised two categories: 65-79, and 80 years and 
over.
Sensitivity analyses included estimating IVE for those swabbed 
within 3 days and for those who were not on antivirals before 
swabbing.
3  | RESULTS
Data were received for 3669 patients in the 10 sites. After exclu-
sions, 3483 patients were included in the study. Of these, 1455 
were confirmed positive (any influenza) cases (42%), while 2028 
were negative controls. There were 533 influenza A cases, of which 
376 were confirmed as influenza A(H3N2) and 133 as influenza 
A(H1N1)pdm09 (25 untyped). Of the 928 influenza B, 299 were B/
Yamagata, and 26 B/Victoria, with 603 having no lineage defined. 
There were six A and B virus co-infections and one co-infection for 
A(H3N2) and A(H1N1)pdm09 (Figure 1). Of the 1856 (53%) vacci-
nated patients, 1502 (81%) were vaccinated before week 47 2017, 
7-8 weeks prior to the peak in influenza onset (Figure 2).
3.1 | Influenza A(H3N2)
Cases and controls were similar in terms of median age (81 vs 
80 years), sex (52% vs 53% being male) and vaccine status (60% vs 
62% vaccinated in the current and 61% vs 62% in the previous sea-
son) (Table 1). One vaccinated patient (<0.1%; a control) received 
quadrivalent, and the others received trivalent inactivated influenza 
vaccine. All vaccines were egg-propagated. Over 90% of both cases 
and controls had at least one underlying chronic condition (P = .360), 
the main one of which was heart disease, with almost two-thirds of 
both cases and controls affected (P = .283; Table 1). More controls 
than cases had lung disease (P = .027), but more cases than controls 
had rheumatic disease (P = .002; Table 1).
The pooled adjusted IVE estimate against influenza A(H3N2) was 
24%, with a 95% confidence interval (95% CI) of 2-40%. Adjusted VE 
was 35% (95% CI: 6 to 55) in those aged 65-79 years and 14% (95% CI: 
−22 to 39) in those ≥80 years. Patients with heart disease had an ad-
justed IVE of 39% (95% CI: 17 to 55) and those with lung disease had 
an IVE of 28% (95% CI: −5 to 51). Precision for IVE among patients 
with diabetes, cancer and kidney disease was very low (Table 2).
Adjusted IVE against influenza A(H3N2) was 37% (95% CI: −2 to 
61) among patients vaccinated in this and either of the two previous 
seasons, 35% (95% CI: 12 to 52) among patients vaccinated in all 
three seasons, 22% (95% CI: −50 to 59) for those vaccinated in the 
current season only and 21% (95% CI: −23 to 50) among those vac-
cinated in either of the two previous seasons but not in the current.
In the sensitivity analyses, IVE against influenza A(H3N2) was 
29% (95% CI: 2 to 48) for those swabbed within 3 days and 17% 
(95% CI: −9 to 36) for those who were not on antivirals before 
swabbing.
3.2 | Influenza B
Cases and controls were similar in terms of median age (78 vs 
79 years). A higher proportion of controls than cases were male (56% 
vs 48%; P = .008) and vaccinated in this or the previous season (59% 
vs 44% for both seasons; P < .001) (Table 1). One vaccinated patient 
(<0.1%; a control) received quadrivalent influenza vaccine, and the 
rest received the lineage-mismatched trivalent vaccine. All vaccines 
were egg-propagated. Ninety-three per cent of both cases and con-
trols had at least one underlying chronic condition (P = .527), the 
main one of which was heart disease, with almost two-thirds of both 
cases and controls affected (P = .124; Table 1). More controls than 
cases had lung disease (P < .001), rheumatic disease (P = .004) and 
kidney disease (P = .032; Table 1).
The pooled adjusted IVE for influenza B was 30% (95% CI: 16 to 
41). For patients aged 65-79 years, IVE was 37% (95% CI: 19 to 51) and 
in those ≥80 years, IVE was 19% (95% CI: −7 to 38). Patients with dia-
betes had an adjusted IVE of 48% (95% CI: 28 to 63), those with heart 
disease had an IVE of 30% (95% CI: 12 to 45%), and for lung disease pa-
tients, the IVE was 19% (95% CI: −6 to 39). Low precision was observed 
for IVE in patients with cancer and kidney disease (Table 3).
Adjusted VE against influenza B was 41% (95% CI: 12 to 61) for 
those vaccinated in both the current and either of the two prior 
seasons, 35% (95% CI: 20 to 48) for those vaccinated in all three 
seasons, 25% (95% CI: −20 to 54) for those only vaccinated in this 
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season and 17% (95% CI: −16 to 41) for those vaccinated only in one 
of the two previous seasons.
In sensitivity analyses, IVE against influenza B was 33% (95% CI: 
14 to 47) for those swabbed within 3 days and 29% (95% CI: 14 to 41) 
for those who were not on antivirals before swabbing.
4  | DISCUSSION
Our results suggest VE against influenza A(H3N2) and B of <31% 
in older hospitalised adults, with lower VE point estimates in those 
aged 80 years and over (<20%) than in those aged 65-79 years 
(>34%), although 95% CIs were wide. Considering previous vacci-
nation over this and the prior two seasons (2015-16 and 2016-17), 
a similar pattern was suggested for both influenza A(H3N2) and B, 
with IVE point estimates being higher among patients who had been 
vaccinated in the current season and both or either of the previous 
two, than for those vaccinated only in the current season, suggesting 
boosting of residual protection from previous vaccination (although 
95% CIs were wide).
Adjusted IVE against hospitalised influenza A(H3N2) among the 
elderly in the European region was 24%, only slightly higher than 
that found in the previous 2016-17 season (17%).7 Our estimate was 
in line with other estimates globally for the 2017-18 season, most of 
F I G U R E  1   Flow chart of inclusions to the I-MOVE hospital study Europe, influenza season 2017-18 
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which were below 50%,8,9 as they have been for almost a decade.10-17 
A recent systematic review of studies using the test-negative design 
estimated a pooled IVE of 24% (95% CI: −6 to 45) against influenza 
A(H3N2) in older adults (>60 years) for the consecutive seasons 2004-
2015.18 Importantly, even when the vaccine matches the circulating 
viral strain for influenza A(H3N2), adaptations of the vaccine viruses to 
propagation in eggs can result in antigenic changes. The adaptation of 
a loss of glycosylation site on the influenza haemagglutinin, for exam-
ple, was hypothesised to contribute to the poor VE against influenza 
A(H3N2) seen in the 2014-15 and 2016-17 seasons.19
TA B L E  1   Characteristics of influenza A(H3N2) and B hospitalised cases (n = 376 and 928) and test-negative controls (n = 1530 and 1905) 
included in the I-MOVE hospital study, Europe, influenza season 2017-18*
 
Influenza A(H3N2) Influenza B
N = 376 cases/ 
total (%)
N = 1530 Test-negative 
controls/Total (%)
N = 928 cases/ 
total (%)
N = 1905 Test-negative 
controls/Total (%)
Median age in years (interquartile range) 81 (73-86) 80 (73-86) 78 (72-84) 79 (72-85)
Missing values 0 0 0 0
Characteristic
Aged 65-79 y 165/376 (43.9) 744/1530 (48.6) 528/928 (56.9) 981/1905 (51.5)
Male 193/375 (51.5) 810/1530 (52.9) 448/926 (48.4) 1023/1905 (53.7)
Vaccination status
Seasonal influenza vaccination 2017-18 224/376 (59.6) 952/1530 (62.2) 405/928 (43.6) 1122/1905 (58.9)
Seasonal influenza vaccination 2016-17 225/372 (60.5) 946/1521 (62.2) 401/912 (44.0) 1108/1878 (59.0)
Underlying conditions
Heart disease 242/373 (64.9) 941/1524 (61.7) 565/925 (61.1) 1216/1897 (64.1)
Lung disease 150/372 (40.3) 712/1524 (46.7) 335/928 (36.1) 879/1897 (46.3)
Diabetes 122/375 (32.5) 456/1527 (29.9) 270/928 (29.1) 568/1900 (29.9)
Rheumatic disease 85/373 (22.8) 241/1520 (15.9) 98/924 (10.6) 275/1892 (14.5)
Kidney disease 77/373 (20.6) 324/1524 (21.3) 156/926 (16.8) 384/1898 (20.2)
Cancer 75/376 (19.9) 339/1527 (22.2) 167/926 (18.0) 403/1901 (21.2)
Obesity 39/371 (10.5) 125/1521 (8.2) 110/923 (11.9) 184/1896 (9.7)
Immunocompromised 16/374 (4.3) 85/1518 (5.6) 34/925 (3.7) 88/1891 (4.7)
At least one underlying condition 336/376 (89.4) 1382/1529 (90.4) 822/928 (88.6) 1729/1904 (90.8)
At least two underlying conditions 247/376 (65.7) 1024/1529 (67.0) 530/928 (57.1) 1272/1904 (66.8)
Functional impairment 97/374 (25.9) 548/1519 (36.1) 318/922 (34.5) 665/1888 (35.2)
Hospitalisation in past year 186/374 (49.7) 783/1518 (51.6) 401/909 (44.1) 871/1850 (47.1)
Current smoking 58/239 (24.4) 347/1171 (29.7) 189/762 (24.9) 399/1530 (26.2)
Potential for misclassification
Swabbing within 3 d of onset 232/376 (61.7) 933/1530 (61.0) 470/928 (50.6) 1083/1905 (56.9)
Received antivirals before swabbing 46/367 (12.5) 60/1520 (3.9) 144/912 (15.8) 93/1895 (4.9)
Study sites Influenza 
A(H3N2)
Test-negative controls Influenza B Test-negative controls
Spain (Aragon and País Vasco regions) 155/376 (41.2) 539/1530 (35.2) 252/928 (27.2) 515/1905 (27.0)
Spain (Navarra region) 130/376 (34.6) 405/1530 (26.5) 196/928 (21.1) 366/1905 (19.2)
Finland 31/376 (8.2) 87/1530 (5.7) 14/928 (1.5) 91/1905 (4.8)
Netherlands 19/376 (5.1) 84/1530 (5.5) 63/928 (6.8) 105/1905 (5.5)
Portugal 18/376 (4.8) 67/1530 (4.4) 48/928 (5.2) 65/1905 (3.4)
France 10/376 (2.7) 233/1530 (15.2) 60/928 (6.5) 262/1905 (13.8)
Croatia 5/376 (1.3) 15/1530 (1.0) 23/928 (2.5) 16/1905 (0.8)
Lithuania 5/376 (1.3) 48/1530 (3.1) 74/928 (8.0) 53/1905 (2.8)
Italy 1/376 (0.3) 28/1530 (1.8) 90/928 (9.7) 351/1905 (18.4)
Romania 2/376 (0.5) 24/1530 (1.6) 108/928 (11.6) 81/1905 (4.3)
*In bold type are those proportions of characteristics in controls for which Fisher's exact test was P < .05 when compared with cases. 
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Against influenza B, despite a lineage mismatch in the trivalent 
vaccine component this season (B/Yamagata in circulation vs B/
Victoria in the trivalent vaccine), IVE was 30%, implying the pos-
sibility of cross-protection.20 This IVE is lower, however, than the 
52% seen in 2015-16, when there was also a lineage mismatch for B 
(albeit the other way around, with B/Yamagata in the vaccine and B/
Victoria in circulation).21,22 Colleagues in Canada and Spain studying 
all age groups in an outpatient setting found a slightly higher IVE 
against influenza B than we did for the 2017-18 season (39%; 95% CI: 
23 to 52 and 41%; 95% CI: 20 to 56, respectively),23,24 while another 
Spanish study with the same inpatient setting but in those >60 years 
found a similar result to ours (26%; 95% CI: −9 to 49).25
Older adults (aged 65 years and above) are known to be at in-
creased risk of severe influenza requiring hospitalisation, especially 
those with underlying co-morbid conditions.26 Some of these con-
ditions (such as cancer, diabetes, heart and lung diseases) are more 
prevalent in this age group, in particular cardiovascular disease, the 
most common chronic condition to affect older adults with influ-
enza.27 This was seen in our study, with almost two-thirds of pa-
tients with either type of influenza, as well as test-negative controls, 
having heart disease (Table 1), while the prevalence of each of the 
other co-morbid conditions measured was below 50%.
Vaccination against influenza has been described as having low or 
very low effectiveness among the older adult population,28 as well as 
among patients with these co-morbid conditions.29-33 Yet, influenza 
vaccination is considered the best available public health interven-
tion to protect against influenza infection, and there is evidence of 
reduction in severe outcomes from influenza (hospitalisation8,34,35 or 
TA B L E  2   Seasonal influenza vaccine effectiveness (IVE) against influenza A(H3N2) overall and stratified by patients’ characteristics, 
I-MOVE hospital study, Europe, influenza season 2017-18
Population/stratification characteristic Vaccinated/cases Vaccinated/controls Adjusted IVE 95% CI
Aged 65 y and above—age/timea 219/359 922/1413 24 (2;40)
Aged 65 y and above—full modelb 219/359 922/1413 24 (2;40)
Aged 65-79 yc 86/155 422/672 35 (6;55)
Aged 80 y and abovec 133/204 500/741 14 (−22;39)
By underlying disease
One or no chronic conditionsd 55/102 233/398 32 (−10;58)
Two or more chronic conditionse 165/258 689/1015 21 (−7;41)
Heart diseasee 134/235 578/859 39 (17;55)
Lung diseasee 89/149 454/677 28 (−5;51)
Diabetesf 84/121 291/429 -5 (−67;33)
Cancere 54/75 215/323 -9 (−96;39)
Kidney diseaseg 51/74 199/307 -13 (−104;37)
By previous vaccinationb N (cases) N (controls)   
Unvaccinated in all three seasons 95 309 ref.  
Vaccinated in either prior season only 36 137 21 (−23;50)
Vaccinated current season only 14 51 22 (−50;59)
Vaccinated current and either prior 
season
30 119 37 (−2;61)
Vaccinated all three seasons 160 720 35 (12;52)
Sensitivity analyses
Swabbed within 3 db 133/222 568/876 29 (2;48)
Swabbed within 3 d, excluding day 0h 116/199 485/749 34 (8;53)
No antivirals before swabbingi 199/313 909/1388 17 (−9;36)
aAge/time: adjusted for study site, age (modelled as a linear term) and onset date (three phases: early, peak and late). 
bFull model: adjusted as for age/time model, sex and presence of any chronic condition. 
cAdjusted as for age/time model, sex and number of chronic conditions (modelled as a categorical variable: none, one, two or more). 
dAdjusted for study site, sex, age (modelled as a linear term) and onset date (modelled as a categorical variable using onset month). 
eAdjusted as for age/time model and sex. 
fAdjusted for study site, sex, age (modelled as a linear term) and onset date (modelled using a restricted cubic spline [RCS] with 5 knots). 
gAdjusted for study site, sex, age (modelled using a RCS with 3 knots) and onset date (modelled using a RCS with 5 knots). 
hAdjusted for study site, sex, age (modelled using a RCS with 3 knots), onset date (three phases: early, peak and late) and presence of any chronic 
condition. 
iAdjusted for study site, sex, age (modelled as a linear term), onset date (modelled using a RCS with 5 knots) and presence of any chronic condition. 
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mortality36) in older adults, particularly for those with chronic co-mor-
bidities. Our results for the 2017-18 season suggest vaccine protection 
from severe influenza A(H3N2) for about one in four hospitalised older 
adults, and for about two in five of these patients with heart disease. 
Protection from severe influenza B was seen for almost one in three 
hospitalised older adults (similar to the protection observed for those 
with heart disease), and for almost one in two of those with diabetes.
Different studies have had inconsistent results for the effect 
of previous vaccination on IVE, reflected in the recently published 
review by Ramsay et al.37 McLean et al's38 study looking at eight 
seasons of IVE in one population in the United States showed that 
IVE was similar for those vaccinated in the current season only, or 
the previous season only, or in both seasons, for both influenza 
A(H3N2) and B, and was highest in those whose vaccination his-
tory was unvaccinated during the previous 5 years. Martínez-Baz 
et al39 found protection against influenza A(H3N2) and B for 
vaccination received in prior seasons. Rondy et al40 found that 
regardless of previous season vaccination, current season vacci-
nation offered some protection against influenza A(H3N2) and 
B for hospitalised older adults in Europe. For European primary 
care patients, Valenciano et al13 detected no apparent pattern for 
the effect of previous vaccination on IVE. The antigenic distance 
(AD) hypothesis anticipates interference with current vaccine ef-
fect by prior season vaccination when two conditions for AD are 
both fulfilled: (a) AD is small between the two vaccines; and (b) 
AD is large between the prior vaccine and the current circulat-
ing strain.41 Based on circulating strains this season42 and recom-
mended vaccines for this and the previous two seasons,2,43,44 the 
AD hypothesis would only be fulfilled for influenza B, and only 
for those vaccinated in 2016-17. The expectation would thus be 
TA B L E  3   Seasonal influenza vaccine effectiveness against influenza B overall and stratified by patient characteristics, I-MOVE hospital 
study, Europe, influenza season 2017-18
Population/stratification characteristic Vaccinated/cases Vaccinated/controls Adjusted IVE 95% CI
Aged 65 y and above—age/timea 403/920 1121/1899 31 (17;43)
Aged 65 y and above—full modelb 403/920 1121/1899 30 (16;41)
Aged 65-79 yc 188/522 533/979 37 (19;51)
Aged 80 y and abovec 215/398 588/920 19 (−7;38)
By underlying disease
Fewer than two chronic conditionsd 136/368 312/592 32 (7;50)
Two or more chronic conditionsd 267/555 809/1310 29 (11;43)
Diabetese 117/270 354/568 48 (28;63)
Heart diseasef 248/564 723/1216 30 (12;45)
Cancerf 86/167 250/403 20 (−21;47)
Lung diseaseg 183/334 555/879 19 (−6;39)
Kidney diseasef 85/156 237/384 4 (−48;38)
By previous vaccinationb N (cases) N (controls)   
Unvaccinated in all three seasons 336 507 ref.  
Vaccinated in either prior season only 74 161 17 (−15;41)
Vaccinated current season only 30 73 25 (−20;53)
Vaccinated current and either prior season 41 118 41 (12;61)
Vaccinated all three seasons 304 882 35 (20;48)
Sensitivity analyses Vaccinated/cases Vaccinated/controls   
Swabbed within 3 db 225/467 669/1081 33 (14;47)
Swabbed within 3 d, excluding day 0h 200/420 578/940 34 (15;49)
No antivirals before swabbingh 382/762 1096/1800 29 (14;41)
aAge/time model: adjusted for study site, age (modelled as a linear term) and onset date (modelled using a restricted cubic spline [RCS] with 5 knots). 
bFull model: adjusted as for age/time model, sex and number of chronic diseases (none, one, two or more). 
cAdjusted for study site, sex, age (modelled as a linear term), onset date (modelled using a RCS with 5 knots) and presence of any chronic diseases for 
the older age group, but number of chronic diseases (none, one, two or more) for the younger age group. 
dAdjusted for study site, sex, age (modelled as a linear term), onset date (modelled using a RCS with 5 knots) and number of chronic diseases (none, 
one, two or more). 
eAdjusted for study site, sex, age and onset date (age and onset date modelled using a RCS with 4 and 5 knots, respectively). 
fAdjusted for study site, sex, age (modelled as a linear term) and onset date (modelled using a RCS with 5 knots). 
gAdjusted for study site, sex, age and onset date (age and onset date modelled using a RCS with 3 and 5 knots, respectively). 
hAdjusted for study site, sex, presence of any chronic diseases, age and onset date (age and onset date modelled using a RCS with 4 and 5 knots, 
respectively). 
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that there would be some interference from prior vaccination, at 
least for patients with influenza B. In contrast, in our study VE was 
higher for those vaccinated in the current season (for both influ-
enza types) if they were also vaccinated previously.
Our study was limited by small sample size, particularly in pa-
tients with influenza A(H3N2), resulting in lower precision around 
the point estimates. A potential limitation was the low propor-
tion (35%) of influenza B cases with lineage results in our study. 
However, this was obviated by national surveillance data from par-
ticipating countries (where the overall proportion of influenza B 
cases with lineage was 56%; data not shown), as well as data from 
Flu News Europe (where the proportion of influenza B cases from 
sentinel sites across the EU with lineage was 48%3), both of which 
confirmed that 95% or more of influenza B cases with lineage were 
B\Yamagata. The benefits of this study are in the use of the same 
protocol by all study sites, the low numbers of missing data for all 
variables (see Table 1), and the study design, which ensures that 
all patients hospitalised in participating sites with influenza symp-
toms are included and tested. Only laboratory-confirmed patients 
are classified as cases, thus eliminating misclassification bias. The 
sensitivity of PCR may decrease over time from symptom onset, 
but restricting analysis to cases swabbed within 3 days gave sim-
ilar results, suggesting that misclassification was unlikely to have 
occurred.
5  | CONCLUSION
For the 2017-18 season among hospitalised older adults, IVE against 
influenza B was greater than that against A(H3N2), despite a triva-
lent vaccine and circulating B lineage mismatch, suggesting some 
cross-protection (as quadrivalent vaccine was used in <0.5% of this 
population). Antigenic changes due to egg-adaptation of the vaccine 
strain could have contributed to the low IVE against A(H3N2). Our 
results suggest lower IVE against both influenza A(H3N2) and B in 
those ≥80 years than in those aged 65-79 years. We reinforce the im-
portance of influenza vaccination in older adults as, even in seasons 
using trivalent vaccine with circulating influenza B lineage mismatch 
and adaption of the egg-propagated vaccine virus, it remains preven-
tive against severe influenza for at least one in four of this population.
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